Cargando…

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis

Existing evidence is inconclusive whether meropenem dosing should be adjusted in patients receiving extracorporeal membrane oxygenation (ECMO). Therefore, the aim of this observational matched cohort study was to evaluate the effect of ECMO on pharmacokinetic (PK) variability and target attainment (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gijsen, Matthias, Dreesen, Erwin, Annaert, Pieter, Nicolai, Johan, Debaveye, Yves, Wauters, Joost, Spriet, Isabel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234236/ https://www.ncbi.nlm.nih.gov/pubmed/34208553 http://dx.doi.org/10.3390/microorganisms9061310

Ejemplares similares

Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function
por: Gijsen, Matthias, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study
por: Gijsen, Matthias, et al.
Publicado: (2021)

Meropenem Stability in Human Plasma at −20 °C: Detailed Assessment of Degradation
por: Gijsen, Matthias, et al.
Publicado: (2021)

Isavuconazole Exposure in Critically Ill Patients Treated with Extracorporeal Membrane Oxygenation: Two Case Reports and a Narrative Literature Review
por: Mertens, Beatrijs, et al.
Publicado: (2023)

Pharmacokinetic Variability and Target Attainment of Fluconazole in Critically Ill Patients
por: Van Daele, Ruth, et al.
Publicado: (2021)

The impact of extracorporeal membrane oxygenation on the exposure to isavuconazole: a plea for thorough pharmacokinetic evaluation
por: Mertens, Beatrijs, et al.
Publicado: (2022)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
por: Gan, Yuhong, et al.
Publicado: (2023)

Pharmacokinetics of Antibiotics in Pediatric Intensive Care: Fostering Variability to Attain Precision Medicine
por: Gijsen, Matthias, et al.
Publicado: (2021)

Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid
por: Van Daele, Ruth, et al.
Publicado: (2021)

Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation
por: Lee, Dong-Hwan, et al.
Publicado: (2021)

Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies
por: Jansen, Anouk M. E., et al.
Publicado: (2023)

External Validation of the Augmented Renal Clearance Predictor in Critically Ill COVID-19 Patients
por: Huang, Chao-Yuan, et al.
Publicado: (2023)

Pharmacokinetics and Monte Carlo Simulation of Meropenem in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation
por: Lee, Jae Ha, et al.
Publicado: (2021)

The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study
por: Shekar, Kiran, et al.
Publicado: (2014)

Meropenem therapy in extracorporeal membrane oxygenation patients: an ongoing pharmacokinetic challenge
por: Honore, Patrick M., et al.
Publicado: (2015)

Population Pharmacokinetics of Vancomycin and Meropenem in Pediatric Extracorporeal Membrane Oxygenation Support
por: Zylbersztajn, Brenda, et al.
Publicado: (2021)

Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
por: Carlier, Mieke, et al.
Publicado: (2013)

Dose Optimization of Meropenem in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation in Critically Ill Cardiac Patients: Pharmacokinetic/Pharmacodynamic Modeling
por: Kang, Soyoung, et al.
Publicado: (2022)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
por: Bhavnani, S. M., et al.
Publicado: (2022)

Systematic Comparison of Hospital-Wide Standard and Model-Based Therapeutic Drug Monitoring of Vancomycin in Adults
por: Gastmans, Heleen, et al.
Publicado: (2022)

Can augmented renal clearance be detected using estimators of glomerular filtration rate?
por: Gijsen, Matthias, et al.
Publicado: (2020)

Pharmacokinetics of meropenem in critically ill patients in Saudi Arabia
por: Alsultan, Abdullah, et al.
Publicado: (2021)

Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?
por: Kantasiripitak, Wannee, et al.
Publicado: (2020)

Reproducibility of fluid status measured by bioelectrical impedance analysis in healthy volunteers: a key requirement to monitor fluid status in the intensive care unit
por: Gijsen, Matthias, et al.
Publicado: (2021)

Software- and TDM-Guided Dosing of Meropenem Promises High Rates of Target Attainment in Critically Ill Patients
por: Chiriac, Ute, et al.
Publicado: (2023)

Pharmacokinetics of meropenem in children with sepsis undergoing extracorporeal life support: A prospective observational study
por: Wang, Yixue, et al.
Publicado: (2021)

Improving the efficacy for meropenem therapy requires a high probability of target attainment in critically ill infants and children
por: Wang, Zeming, et al.
Publicado: (2022)

Isavuconazole in the Treatment of Aspergillus fumigatus Fracture-Related Infection: Case Report and Literature Review
por: Mertens, Beatrijs, et al.
Publicado: (2022)

A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation
por: Van Daele, Ruth, et al.
Publicado: (2021)

Pharmacokinetics of meropenem during continuous renal replacement therapy in critically ill patients
por: Solé Violan, J, et al.
Publicado: (2014)

Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients
por: Goncalves-Pereira, João, et al.
Publicado: (2014)

Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients
por: Abdulla, Alan, et al.
Publicado: (2020)

Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem
por: Sanz Codina, Maria, et al.
Publicado: (2022)

Evaluation of pharmacokinetic and pharmacodynamic parameters of meropenem in critically ill patients with acute kidney disease
por: Hassanpour, Rezvan, et al.
Publicado: (2021)

Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients
por: Heil, Emily, et al.
Publicado: (2017)

Adequate Antimicrobial Dosing in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation: Where to Go from Here?
por: Spriet, Isabel, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
por: Berrino, Pasquale Maria, et al.
Publicado: (2023)

Evaluation of the MeroRisk Calculator, A User-Friendly Tool to Predict the Risk of Meropenem Target Non-Attainment in Critically Ill Patients
por: Liebchen, Uwe, et al.
Publicado: (2021)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
por: Wenzler, Eric, et al.
Publicado: (2020)

Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis
por: Pařízková, Renata Černá, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_isrrd4hi9nn1f6cdi9i3u7gj8s